权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Role of Podocalyxin in Osteoclast Activity and Bone Metabolism

足萼蛋白在破骨细胞活性和骨代谢中的作用

基本信息

批准号：
8793679
负责人：
Megan M Weivoda
金额：
$ 3.21万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-05-22 至 2014-12-19
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8793679
关键词：
A Mouse Address Adenoviruses Adult Affect Age Age-Months Age-Related Bone Loss American Animal Model Biochemical Markers Biological Biology Bone Density Bone Marrow Bone Pain Bone Regeneration Bone Resorption Bone remodeling Cell Adhesion Cell Lineage Cells Data Development Disease Endocrine Estrogens Exhibits Fellowship Female Femur Genetic Models Genotype Goals Gonadal Steroid Hormones Guanosine Triphosphate Phosphohydrolases Hematopoietic In Vitro Knock-out Lead Left Length Measures Mediating Mediator of activation protein Metabolic Bone Diseases Mus Neoplasm Metastasis Operative Surgical Procedures Osteoblasts Osteoclasts Osteogenesis Osteoporosis Pathway interactions Phenotype Postmenopause Preparation Production Publications Reporting Research Risk Role Second lumbar vertebra Serum Sialoglycoproteins Signal Transduction Skeleton Tail Testing Training Wild Type Mouse Work X-Ray Computed Tomography adipocyte differentiation adipokines aging population bisphosphonate bone bone loss bone mass bone metabolism cancer cell career career development cost experience extracellular in vivo interest macrophage male migration mouse model mutant new therapeutic target osteoporosis with pathological fracture podocalyxin precursor cell prevent public health relevance scaffold sex skeletal skills spine bone structure therapeutic target tool

项目摘要

DESCRIPTION (provided by applicant): Current treatments for osteoporosis, such as the bisphosphonates, target osteoclast-mediated bone resorption. While these agents effectively reduce bone loss, this is complicated by an associated decrease in bone remodeling resulting in diminished bone formation and repair. Mounting evidence suggests that the presence of osteoclasts is required for bone formation by osteoblasts. Thus, the long term goal of this project is to identify potential therapeutic targets to inhibit osteoclast activity while preservin the anabolic effects of osteoclasts on osteoblasts and bone formation. One potential target to inhibit osteoclast activity without reducing the anabolic effects of osteoclasts is podocalyxin (PODXL). PODXL has previously been identified as a mediator of cell adhesion expressed by cells of the hematopoietic lineage. Preliminary data show that deletion of PODXL specifically in the hematopoietic lineage/osteoclast precursors (Vav/PODXLdel) leads to a high bone mass phenotype in female adult mice and increased osteoblast numbers. While these mice exhibit increased osteoclast numbers, resorption by these osteoclasts is impaired. Of particular interest, this high bone mass phenotype is evident only in female mice suggesting that the loss of PODXL is exacerbated by the presence or absence of specific sex steroids. Vav/PODXLdel bone marrow derived osteoclasts exhibit reduced activation of the Rac1 GTPase. Several groups have demonstrated that Rac1 activation is reduced by estrogen and this contributes to sex specific phenotypes in animal models. The central hypothesis of my project is that PODXL is necessary for optimal Rac1 activation; deletion of PODXL exacerbates the effect of estrogen to inhibit Rac1 activation, leading to impaired osteoclast resorption and a high bone mass in estrogen-sufficient female mice. My objectives are to characterize how the bone phenotype of Vav/PODXLdel mice is impacted by sex steroids in an in vivo mouse model and to define the mechanism by which PODXL modulates Rac1 activation and osteoclastic bone resorption. Understanding the mechanism by which PODXL facilitates Rac1 activation in pre-osteoclasts and how this is impacted by circulating sex steroids may lead to novel therapeutic targets to inhibit osteoclast activity without disturbing the anabolic effects of osteoclasts on the skeleton. Additionally, studying the role of sex steroids in the Vav/PODXLdel bone phenotype may elucidate mechanisms that contribute to postmenopausal and age-related bone loss.

描述（由申请人提供）：目前治疗骨质疏松症的药物，如双磷酸盐，靶向破骨细胞介导的骨吸收。虽然这些药物有效地减少了骨质流失，但由于骨重塑的相关减少导致骨形成和修复的减少，情况变得复杂。越来越多的证据表明，破骨细胞的存在是成骨细胞形成骨所必需的。因此，该项目的长期目标是确定潜在的治疗靶点，以抑制破骨细胞的活性，同时保持破骨细胞对成骨细胞和骨形成的合成代谢作用。一个抑制破骨细胞活性而不降低破骨细胞合成代谢作用的潜在靶点是足alyxin （PODXL）。PODXL先前已被确定为造血谱系细胞表达的细胞粘附介质。初步数据显示，在造血谱系/破骨细胞前体（Vav/PODXLdel）中特异性地缺失PODXL会导致雌性成年小鼠的高骨量表型和成骨细胞数量增加。当这些小鼠表现出增加的破骨细胞数量时，这些破骨细胞的吸收受损。特别有趣的是，这种高骨量表型仅在雌性小鼠中明显，这表明特定性类固醇的存在或缺失加剧了PODXL的缺失。Vav/PODXLdel骨髓源性破骨细胞表现出Rac1 GTPase活性降低。一些研究小组已经证明，雌激素降低了Rac1的激活，这有助于动物模型中的性别特异性表型。我的项目的中心假设是，PODXL对于最佳的Rac1激活是必要的；PODXL的缺失加剧了雌激素抑制Rac1激活的作用，导致雌激素充足的雌性小鼠破骨细胞吸收受损和骨量增高。我的目标是在体内小鼠模型中描述性类固醇如何影响Vav/PODXLdel小鼠的骨表型，并确定PODXL调节Rac1激活和破骨细胞骨吸收的机制。了解PODXL促进破骨前细胞中Rac1激活的机制以及循环性类固醇对其的影响，可能会导致新的治疗靶点，在不干扰破骨细胞对骨骼的合成代谢作用的情况下抑制破骨细胞的活性。